BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2024
0mins
Should l Buy ?
Source: NASDAQ.COM
Quarterly Performance: BioHarvest Sciences Inc. reported a quarterly loss of $0.16 per share, significantly worse than the expected loss of $0.05, and revenues of $6.54 million, missing estimates by 2.26%. The company has only surpassed consensus EPS estimates once in the last four quarters.
Market Outlook: Despite underperforming compared to the S&P 500 this year, the stock holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market. Future performance will depend on management's commentary and earnings estimate revisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
